Noradrenergic and cholinergic modulation of late ERP responses to deviant stimuli
Noradrenergic and cholinergic modulation of late ERP responses to deviant stimuli
复制标题
DOI：
10.1111/psyp.12544
复制
发表时间：
2015-12-01
期刊：
影响因子：
3.7
通讯作者：
Nieuwenhuis, Sander
中科院分区：
文献类型：
--
作者：
Brown, Stephen B. R. E.;Van der Wee, Nic J. A.;Nieuwenhuis, Sander
研究人员提出了几个关于神经调节系统参与产生ERP的P3组件的假设。为了验证其中的一些假设，我们进行了一项随机安慰剂对照交叉研究，在该研究中，我们研究了(a)可乐定（一种减弱基线去甲肾上腺素能活性的α(2)激动剂）如何调节对异常刺激的晚期阳性ERP反应；(b)东莨菪碱，乙酰胆碱受体的毒蕈碱拮抗剂。我们收集了18名健康志愿者在执行一项有主动和被动任务条件的听觉古怪任务时的脑电图数据。然后，我们使用时空主成分分析（PCA）对ERP波形进行分解。主成分分析显示两个明显的晚期阳性ERP成分：经典顶叶P300和额叶新颖P3。时空因子得分的统计分析表明，在大多数情况下，可乐定和东莨菪碱能增加经典P300的振幅。相比之下，两种药物都降低了新颖性P3的振幅。可乐定和东莨菪碱的相似结果可能反映了去甲肾上腺素能系统和胆碱能系统之间的强烈相互作用。这些结果，结合之前的药理学研究，表明神经调节系统在P300和新颖P3的产生中都起着关键作用。
Researchers have proposed several hypotheses about the neuromodulator systems involved in generating P3 components of the ERP. To test some of these hypotheses, we conducted a randomized placebo-controlled crossover study in which we investigated how the late positive ERP response to deviant stimuli is modulated by (a) clonidine, an alpha(2) agonist that attenuates baseline noradrenergic activity; and (b) scopolamine, a muscarinic antagonist of acetylcholine receptors. We collected EEG data from 18 healthy volunteers during the performance of an auditory oddball task with several active and passive task conditions. We then used temporospatial principal component analysis (PCA) to decompose the ERP waveforms. The PCA revealed two distinct late positive ERP components: the classic parietal P300 and the frontal novelty P3. Statistical analysis of the temporospatial factor scores indicated that in most conditions the amplitude of the classic P300 was increased by clonidine and scopolamine. In contrast, the amplitude of the novelty P3 was decreased by both drugs. The similar pattern of results for clonidine and scopolamine probably reflects the strong interactions between the noradrenergic and cholinergic systems. The results, in combination with previous pharmacological studies, suggest a critical role for both neuromodulator systems in the generation of the P300 and the novelty P3.